22:51
Cybin Receives Expedited Review FDA Breakthrough | Trade To Black
The Dales Report
42:40
Hope for Mental Health Treatment | Professor David Nutt | The Dales Report
59:47
Inside the Mind of an Athlete: Facing the Pressure | Daniel Carcillo | The Dales Report
28:06
Mental Health Revolution: Preparing for Legalization | The Dales Report
22:00
Why This Quarter Could Be Vital for Cybin's FDA Milestones! | TDR Exclusive
30:05
From Data to Dollars: How Biotech Investments are Shaping the Market | The Dales Report
9:16
BREAKING NEWS: MAPS Submits NDA | The Dales Report
30:48
Paradise Found: Is This The World's Best Retreat? | Beckley Retreats | The Dales Report
22:18
Numinus Lowers Burn Rate and Reveals Positive Results | The Dales Report
19:34
A Brighter Future Ahead | $CYBN | The Dales Report
20:46
Cybin's Path to Dominance! | The Dales Report
28:44
Off-Label Mental Health Solutions | Numinus | The Dales Report
26:29
From Stigma to Solutions | Safe Supply (CSE: SPLY) | The Dales Report
20:51
Unleashing a Safer Future (CSE: SPLY) | Safe Supply | The Dales Report
39:34
Emerging Industry: Ride The Wave Of Policy Shifts | Safe Supply | The Dales Report
22:23
Excitement Builds as Awakn Life Sciences Submits Phase 3 Trial I The Dales Report
34:53
Diving into Exciting Emerging Sectors | Cody Shandraw | The Dales Report
38:03
Red Light Holland's Massive Expansion | The Dales Report
29:39
Numinus CEO Provides End of Summer Company Update
22:38
Guidelines for Psychedelic Assisted Therapy Announced
33:48
Zappy Zapolin Reveals The Industries Rapid Growth - TDR Exclusive
41:06
Government’s Support on Advancing Mental Health Treatments - TDR Exclusive
28:25
What To Anticipate From Awakn’s Phase 3 Trial - TDR Exclusive
27:11
Numinus CEO on MDMA-Assisted Therapy Prospects - TDR Exclusive
31:49
How HEALING Reit Will Improve Access to Therapy - TDR Exclusive
22:32
Healing REIT Poised to Build National Real Estate Footprint - TDR Exclusive
17:36
Mindset Pharma Accelerates To Phase 2 In-Patient Trial - TDR Exclusive
17:00
Breaking Down TREAT California’s $5B Goal for Mental Healthcare - TDR Exclusive
29:07
Numinus And MAPS Partnership Explained - TDR Exclusive
21:40
Cybin CEO Reveals $30m Shares Purchase Agreement - TDR Exclusive
31:57
What to Anticipate At the Upcoming MAPS Conference - TDR Exclusive
34:32
Upcoming Catalysts in the Industry Explained - TDR Exclusive
21:33
How Mindset Pharma Dealt Partnership With Otsuka - TDR Exclusive
35:51
CEO Todd Shapiro Reveals Red Light Holland’s Shroom Outlook - TDR Exclusive
21:12
Pharmala Stock Succeeds Through Tough Markets - TDR Exclusive
30:27
Industry's Timelines and Latest Catalyst Explained - TDR Exclusive
24:19
MindMed CEO Explains New Vision For Company - TDR Exclusive
20:59
Numinus CEO Discusses Latest Earnings - TDR Exclusive
14:29
Healing REIT CEO Reveals Future Of Health Clinics - TDR Exclusive
33:29
atai Founder Reveals 14 Reasons To Remain Optimistic - TDR Exclusive
30:26
Psychedelic Stocks’ Promising Outlook For Investors - Psychedelics Exclusive
29:53
Differences Between Numinus & Field Trip Health Explained
35:33
Why Psychedelic Treatments Will Benefit Investors and Healthcare
25:28
Australia Advancing Mental Health Treatments
35:40
Why We Owe This To The People
32:00
Here's What Healthcare Wants To See
26:10
An In-depth Review Of Numinus Q1 Results
36:00
Numinus Outlines 2023 Strategy - Trade To Black
29:29
Legal Psychedelics Pathway to Revenue - Trade To Black 18
29:19
Investor Predictions for Cannabis, Psychedelics, and Crypto -Trade To Black #15
17:58
Tight Share Float For This Company - Trade To Black #14
26:15
The Future Of Psychedelic Therapy Explained - Trade To Black #13
21:01
Mindset CEO Reveals His Strategy - Trade To Black #12
28:57
How Legal Psychedelics Can Cure Mental Health - Trade to Black #10
LIVE
[Private video]
18:12
Wonderland Miami: What To Expect, Mike Tyson and Psychedelic Medicine - Trade To Black #4
16:41
Psychedelic Breakthrough Research in 2023 Explained - Trade To Black #3
13:08
Braxia's $6-million acquisition of telemedicine platform KetaMD addresses “the access gap.”
32:22
LSD, Psilocybin, MDMA Will Change the World
34:44
What atai Life Sciences 9 Clinical Trials Means For Investors
25:50
Psychedelics Potentially Good For Mind, What About the Heart? | Tessellate
24:56
Numinus Predicts Big Things On The Horizon | CEO Payton Nyquvest
25:08
Psychedelic Company Partnering With CAMH | Mindset Pharma
21:45
Optimind Pharma Poised To Help First Nations Communities | COO Dr. Mike Hart & CEO Tomas Sipos
35:19
John Hopkins Receives $4M Grant For Smoking Cessation Trial | CEO Josh Bartch
17:50
$74.5 Million In The Bank For Field Trip | CEO Ronan Levy
14:13
Numinus Completes Novamind Acquisition | CEO Payton Nyquvest
20:38
FDA Could Legalize MDMA By 2023 | PharmAla Biotech
21:58
Alcohol & Internet Usage On The Rise | Awakn Life Sciences
25:46
Psychedelic Leader Reports Earnings | CEO Florian Brand - atai Life Sciences
13:55
Numinus To Administer First Psilocybin Therapy | CEO Payton Nyquvest
22:16
HAVN Life Sciences Signs New Deal | CEO Tim Moore
16:56
Kevin Harrington—An Original Shark from Shark Tank—Backs The Psychedelics Industry
23:11
Why Athletes Like Psychedelics | Ian MacCall, Former UFC Star
15:30
Major Acquisition Announced This Week | Payton Nyquvest - CEO Numinus Wellness
23:42
The Ketamine Revolution May Reshape Addiction Treatment | CEO and CRO of AWAKN
12:52
Why Natural Psilocybin? | Dane Stevens - CMO & Director of Optimi Health
7:55
The Difference Between Natural & Synthesized | Sharan Sidhu - GM & Science Officer Numinus Wellness
16:05
Numinus At The Forefront of MDMA | Payton Nyquvest - CEO Numinus Wellness
13:33
Ketamine To Treat Alcoholism? | Celia Morgan Awakn Life Sciences
21:16
THIS Company Has The Keys To Psychedelic Success| Payton Nyquvest - CEO Numinus Wellness
13:09
Tony Robbins Sings Cybin's Praises | CEO Doug Drysdale
7:04
Psychedelics & Mental Disorders: Recent Psilocybin Study Shows Promising Results
13:11
What Is A 2nd Generation Psychedelic? | Mindset Pharma
11:08
Consolidation Coming In Psychedelics | MindCure & Awakn
15:09
Non Hallucinogenic LSD? BetterLife Pharma on Psychedelic Investors Radar
6:52
Wonderland Psychedelic Conference: Shroom Boom Is Here To Stay! | Microdose
11:24
Treatment Needed For TBI: Wesana Health | Wesana Health Holdings
13:14
Psychedelic Therapeutic Advancement Framework | Braxia Scientific
5:45
Access To Treatment With Its Own Insurance Company | Revitalist Lifestyle
11:53
MYND Life Sciences Talks Biomarkers & More | Dr. Lyle Oberg
9:59
Are Psychedelics A Viable Industry? | Numinus
7:44
Non-Hallucinogenic Psychedelic For Real | Diamond Therapeutics
18:48
Inside The True Value Of Psychedelic Trials | Tim Moore CEO HAVN Life Sciences
19:57
Mindset Pharma Gains New Insights In Psychedelics | CEO James Lanthier and CSO Joe Araujo
14:26
Psilocybin, a Game-Changer in Battle Against Cancer? | Aquilino Cancer Center, Dr. Manish Agrawal
20:01
Psychedelic Companies: Reciprocity Or Bust | Tabula Rasa Ventures
9:14
Health Care Practitioners Denied Psilocybin Access | Spencer Hawkswell CEO TheraPsil
19:05
Breakthrough Breast Cancer Research | Revive Therapeutics
18:11
The Formula For Addiction Treatment? | Jeeshan Chowdhury CEO Journey Colab
27:21
Unlocking The Potential Of DMT | Timothy Ko CEO Entheon, Andrew Hegle CSO Entheon
24:41
Inside Psychedelic Clinical Trials | Danny Motyka CEO Psygen & Peter van der Heyden CSO Psygen
18:43
Empowering Psychotherapists To Offer Psychedelic Therapy | Jonathan Sabbagh CEO Journey Clinical
19:52
What Are Psychedelic Investment Funds Looking For? | Tim Schildt Co-Founder Palo Santo
18:49
Is HAVN Undervalued After Big Purchase? | HAVN Life CEO Tim Moore
Whats Holding Back Psychedelic Research? | Instituto Phaneros
23:58
Remarkable Secrets Of Ketamine | Dr. Reid Robison CMO NovaMind
27:46
Trusting The Psychedelic Process? | Josh Bartch CEO Mydecine
Big Things For Psychedelics in 2022 | Mindcure CEO Kelsey Ramsden
25:24
Fighting For Happiness With Psychedelics | Zappy Zapolin
19:51
"World Needs More Antiviral Pills"| Daniel Cohen CEO Pharmadrug
27:43
Revitalist Focuses On Training In Psychedelic Space | CEO Kathryn Walker
15:35
Psychedelics Gains Big Pharma Endorsement | James Lanthier CEO Mindset Pharma
18:08
Mydecine Hits Milestone With New AI-Powered Program | Chief Science Officer Rob Roscow
16:27
Greater Change Coming To Psychedelics | Numinus CEO Payton Nyquvest
19:17
Groundbreaking Ketamine Study Shows MAJOR Potential | AWAKN CEO Anthony Tennyson
14:58
Telemedicine Disrupt Traditional Healthcare? | NostaLab CEO John Nosta
16:59
Braxia Scientific Achieves Psilocybin Milestone | Braxia CEO Dr. Roger McIntyre
15:25
Powerful Expectations For Psychedelics | Mydecine
21:49
Psilocybin Advantage You Need To Know | Tryp Therapuetics
12:12
Traditional Doctors See Future In Psychedelics | Mydecine
17:46
Happy Holidays From The Dales Report Team 🎉🥂
15:03
2022 Predictions: "Scaling revolves around three things..." | Mydecine
7:50
Women’s Health & Psychedelics Intersect | Felicity Pharma
19:02
Numinus CEO: Psychedelics Benefit From "Big Rebound" | Payton Nyquvest
18:10
Pharmadrug Clears Hurdle Toward Treatment Of Mild To Moderate COVID
17:56
Psychedelic Investors..."It's About The Data Stupid" | Awakn
24:12
Default Mode Network(DMN): How Psychedelics Affects The Mind | Manoj Doss
18:42
Bye SSRI's, Hello Psychedelics | Kathryn Walker
25:10
How Psychedelics Alters Mind | Chris Timmermann
26:06
Treating Addiction By Taking Drugs | Mydecine
18:34
This Psychedelic Company Is A Big Deal | Awakn Life Sciences
Ibogaine Addiction Treatments & MDMA Assisted-Psychotherapy | MindCure
21:18
Oral Anti-Viral Pill; DTM Positive Effects For Glaucoma | PharmaDrug
15:07
Flurotest (TSXV: TEST) CEO Bill Phelan
19:25
40 Years Of Psychedelic Research
14:22
Stock Up Over 70%
22:34
Awakn’s Partnership & Believing In Psychedelics
11:48
The Rise of Psychedelics in Q4 | Mydecine
12:11
Investors Psyched For Wonderland, Miami Psychedelic Conference
16:55
Telehealth & Mental Health Boom
Numinus Major Expansion
16:43
Big Pharma Good or Bad?
14:32
Cure For Alcohol & Gambling Addiction?
16:19
Cannabis Or Psychedelic Stock? | Revitalist
18:23
Potential Cure for Alzheimer’s Disease?
23:54
How Does A Psychedelic Retreat Work?
15:24
Mydecine: How to Stop Smoking
20:52
Over 70% Psychedelic Success Rate | Mydecine
22:15
Medicine For Woman's Sexuality
16:57
Psychedelics and Eating Disorders
16:36
Small Pharma On DMT Phase 1 Completion
10:34
PharmaTher (CSE:PHRM) CEO Fabio Chianelli
8:55
Revive Therapeutics (CSE: RVV) on The Dales Report
13:46
CEO: Numinus (CSE: NUMI) Payton Nyquvest
10:48
Revive Therapeutics (CSE:RVV): Advantages of Tannin Chitosan
13:25
Mynd Life Sciences CEO Lyle Oberg
12:29
A Psychedelic Company Generating Revenue?
16:34
Frequently Asked Legal Questions About the Psychedelic Space
11:28
Numinus Wellness: Building A Comprehensive Psychedelic-Assisted Therapy Ecosystem
MYND Life Sciences CEO Dr. Lyle Oberg on The Dales Report
10:45
Tryp Therapeutics (CNSX: TRYP) Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board
11:59
Scientific Rigor and Strong Team Pave Way for Tryp Therapeutic’s Continued Growth
16:38
Numinus’ Dr. Evan Wood: There is Nothing Like Psychedelics to Treat Mental Health Challenges
11:22
PsyBio Therapeutics (TSXV: PSYB) Coming To Market on TSXV
13:34
Mydecine Innovations' Josh Bartch: The Last 12 Months Have Been Monumental For The Industry
14:21
I Believe DMT is Important: PharmaDrug CEO Daniel Cohen on Psychedelic and Cannabis Strategies
20:18
Mydecine Co-Founder Damon Michaels: It’s Time To Make Alternative Medicine Traditional Medicine
18:01
Similar to Cannabis Capital Market Structure: Horizons ETFs CEO on Psychedelics Industry
11:34
Havn CEO Tim Moore on Psychedelics Industry: “We’re an Industry of Hope”
Numinus Science Officer/GM Sharan Sidhu: We Won’t Patent IP That Makes Psychedelics Inaccessible
Numinus (TSXV: NUMI) CEO Payton Nyquvest Speaks on $40m Bought Deal Offering
14:48
CSO Rob Roscow: Transforming Research From Mydecine's 3 Pillars Into Repeatable Medicine
Kind of Like the Netflix of Psychedelics: CEO Kelsey Ramsden on iSTRYM
7:42
Mydecine CSO Rob Roscow on Psychedelic Therapy Potential for Depression and PTSD
11:09
Cannabis Paved the Way for Psychedelics - Derrick Welsh of Revive Therapeutics
19:58
Wesana Health CEO Daniel Carcillo Gets Personal
11:00
Psychedelic Experience 'Promising' in Treating PTSD - Mydecine CMO Dr. Rakesh Jetly
Dr. Jetly on Mydecine (NEO: MYCO) Clinical Trials for Psilocybin Assisted Psychotherapy
14:02
Tryp Therapeutics CEO Greg McKee: The Possibilities Of Psilocybin Is Off The Charts
18:47
Pharmadrug CEO Daniel Cohen Provides Updates On DMT Research, Operations In Germany
15:59
Dr. Mike Hart on Psychedelics for Treatment of Depression
18:40
MindCure’s Kelsey Ramsden on Psychedelic Rollout: It’s Not Just Regulation; It’s Research
12:25
In The Face of Emerging Research, Numinus’ Upcoming Phase One Trial Is All About Safety And Efficacy
15:40
atai Life Sciences: $453m Cash Position
Can Psilocybin Treat Hyperphagia? Tryp Therapeutics’ Jim Gilligan & Dr. Jennifer Miller Want To Know
17:40
Mydecine CSO Rob Roscow on 2a Clinical Trials and the Road Ahead
17:54
Dr. Mike Hart on How the Psychedelic Industry Can Help Mental Health
CEO Evan Levine: “Our Method Synthesizes Psilocybin Cheaper, Faster, And Greener” Than The Others
11:41
Mike Hart on MDMA-Assisted Therapy for PTSD: Nothing Short of Revolutionary
17:42
Revitalist CEO: 120 Psychedelic Clinics by 2023
Wake Network Inc.: Advancing The World’s First Psilocybin Microdosing Study To Phase 2 Trial
19:00
Neonmind CEO Rob Tessarolo Says Psychedelics Could Potentially Treat Obesity
Wake Network Just Conducted The First Legal Import of Psilocybin To The U.S. From Jamaica
14:49
PharmAla Biotech CEO Nick Kadysh: Investor Sophistication Has Gone Up in Psychedelics
12:37
MYND Life Sciences CEO Dr. Lyle Oberg said His Team Has Found The Switch For Depression
